Objective: To analyze the ability of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) and the fusion of FDG-PET with computed tomography (FDG-PET/CT) to detect synchronous upper gastrointestinal tract (UGI) cancer in newly diagnosed pharyngeal squamous cell carcinoma (SCC). Synchronous UGI cancer is a significant problem in treating pharyngeal SCC, particularly for Japanese populations reported to be at high risk. Good results have been reported from the use of FDG-PET and FDG-PET/CT in staging head and neck SCC (HNSCC). An additional advantage is that both techniques are expected to prove useful in detecting synchronous cancer.
Design: Retrospective analysis of medical records.
Setting: Aichi Cancer Center, Nagoya, Japan.
Patients: Forty-three Japanese patients with pharyngeal SCC were assessed for the ability of FDG-PET and FDG-PET/CT to detect synchronous UGI cancer via a comparison with UGI Lugol chromoendoscopy. The patients had undergone 17 FDG-PET and 26 FDG-PET/CT scans before treatment.
Main Outcome Measure: Sensitivity of FDG-PET and FDG-PET/CT to detect synchronous UGI cancer.
Results: Pathologically, 6 patients with esophageal SCC (14%) and 4 with stomach adenocarcinoma (9%) were diagnosed on the basis of suspect lesions detected by UGI Lugol chromoendoscopy. One patient was found to have stage T2 esophageal cancer by FDG-PET/CT, but no patients had UGI cancer. The sensitivity of detecting T1 UGI cancer by FDG-PET and FDG-PET/CT was 0%.
Conclusions: The choice of diagnostic technique must be based on the site and histologic characteristics of the synchronous tumor. Although FDG-PET and FDG-PET/CT are still the preferred techniques for staging HNSCC, neither replaces Lugol chromoendoscopy for detecting synchronous UGI cancer in high-risk populations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archotol.134.11.1191 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Minimally invasive treatment strategies for submucosal tumors of the upper gastrointestinal tract: Advances in innovative endoscopy-based therapies.
Eur J Surg Oncol
January 2025
Department of Gastroenterology & Hepatology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China; Sichuan University-Oxford University Huaxi Gastrointestinal Cancer Centre, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. Electronic address:
The increasing detection of submucosal tumors (SMTs) in the upper gastrointestinal tract (UGI) is due to the increased clinical use of endoscopy and imaging technology. Some of these SMTs have malignant potential and may cause clinical symptoms. Thus, it is recommended in clinical guidelines to consider resection of these SMTs.
View Article and Find Full Text PDFHigher compliance with the enhanced recovery after surgery protocol improves postoperative recovery and 6-month mortality in upper gastrointestinal surgery.
Surg Pract Sci
December 2024
Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Introduction: The enhanced recovery after surgery (ERAS) protocol has been proven to accelerate recovery without increasing morbidity, but few data are available from developing countries. We aimed to demonstrate the correlation between compliance with the ERAS protocol and short-term outcomes in upper gastrointestinal (UGI) surgery.
Materials And Methods: Patients that underwent esophageal and gastric surgeries during March 2019 to June 2021 were prospectively enrolled in this nonrandomized cohort study.
Basophils may as a risk factor for upper gastrointestinal cancer: a Mendelian randomization (MR) study.
Ecancermedicalscience
November 2024
Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, No 253 Mid Gongye Ave, Haizhu District, Guangzhou 510282, Guangdong Province, China.
Objective: Upper gastrointestinal (UGI) cancers, including esophageal (EC) and gastric (GC) cancers, pose a significant global health challenge. Previous studies have indicated a fundamental correlation between basophil count and the risk of UGI cancer. However, confirming a causal relationship demands further investigation.
View Article and Find Full Text PDFRisk Factors Predicting Outcomes in Advanced Upper Gastrointestinal Cancers Treated With Immune Checkpoint Inhibitors.
Gastroenterology Res
December 2024
Division of Medical Oncology, Department of Internal Medicine, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Background: Immune checkpoint inhibitors (ICIs) have moved to the frontline in recent years to manage upper gastrointestinal (UGI) tumors, such as esophageal and gastric cancers. This retrospective review sheds light on real-world data on ICI-treated UGI tumors to identify risk factors (clinical and pathological) impacting the outcome other than traditional biomarkers (programmed cell death ligand 1 (PD-L1) or microsatellite instability status).
Methods: Patients with UGI tumors who received at least one dose of ICI for stage IV or recurrent disease between January 1, 2015, and July 31, 2021, at The Ohio State University were included in the study.
Oral microbiome dysbiosis is associated with precancerous lesions and disorders of upper gastrointestinal tract: A population-based study.
Am J Gastroenterol
December 2024
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 77 Stockholm, Sweden.
Background And Aims: Oral microbiota may contribute to the development of upper gastrointestinal (UGI) disorders. We aimed to study the association between the microbiome of saliva, subgingival and buccal mucosa, and UGI disorders, particularly precancerous lesions. We also aimed to determine which oral site might serve as the most effective biomarker for UGI disorders.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!